Rita M. Egan

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 390 citations · Full text

Rheumatoid Disorder, Rheumatology, Spirit-p2 Phase 3 +12

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

Michelle Petri, Philip J. Mease, Joan T. Merrill et al. · Arthritis & Rheumatism · 2004 · 144 citations

Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune-privileged site

Rita M. Egan, Chris Yorkey, R.A. Black et al. · The Journal of Immunology · 1996 · 105 citations

In Vivo Behavior of Peptide-Specific T Cells During Mucosal Tolerance Induction: Antigen Introduced Through the Mucosa of the Conjunctiva Elicits Prolonged Antigen-Specific T Cell Priming Followed by Anergy

Rita M. Egan, Chris Yorkey, R.A. Black et al. · The Journal of Immunology · 2000 · 67 citations · Full text

Catastrophic antiphospholipid antibody syndrome presenting with multiple thromboses and sites of avascular necrosis.

Rita M. Egan, R K Munn · PubMed · 1994 · 50 citations

Immunohematology, Vascular Disease, Vasculitis +20